Understanding Incretin Hormones and Their Role in Glucose Metabolism

Incretin hormones are peptides released from enteroendocrine cells in the gastrointestinal tract in response to nutrient ingestion. The two primary incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are responsible for the “incretin effect” — the phenomenon where oral glucose elicits a greater insulin response than intravenous glucose at equivalent blood glucose levels. This effect accounts for approximately 50–70% of postprandial insulin secretion. GLP-1 and GIP bind to specific receptors on pancreatic beta cells, potentiating insulin exocytosis only when blood glucose is elevated, thus reducing the risk of hypoglycemia. Additionally, GLP-1 suppresses glucagon secretion from alpha cells, slows gastric emptying, and promotes satiety through central nervous system pathways. GIP predominantly acts on the pancreas but also influences lipid metabolism and bone turnover. The pleiotropic actions of incretins make them attractive therapeutic targets for type 2 diabetes (T2D) and obesity.

Classes of Incretin-Based Therapies

GLP-1 Receptor Agonists (GLP-1 RAs)

GLP-1 receptor agonists are synthetic analogs of native GLP-1 that resist rapid degradation by dipeptidyl peptidase-4 (DPP-4). These agents bind to and activate GLP-1 receptors, producing effects similar to endogenous GLP-1 but with extended half-lives. GLP-1 RAs are classified by duration of action: short-acting (exenatide twice daily, lixisenatide once daily) and long-acting (liraglutide once daily, semaglutide once weekly, dulaglutide once weekly, and extended-release exenatide). Long-acting agents achieve more sustained pharmacokinetics and greater HbA1c reductions, while short-acting agents provide stronger postprandial glucose control. GLP-1 RAs consistently reduce HbA1c by 1.0–1.5%, promote weight loss (2–7 kg depending on agent), and lower systolic blood pressure. They are associated with a low risk of hypoglycemia except when combined with sulfonylureas or insulin.

DPP-4 Inhibitors (Gliptins)

DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin) are oral agents that prevent enzymatic inactivation of endogenous GLP-1 and GIP, thereby raising their physiological concentrations. They produce more modest glycemic effects than GLP-1 RAs — HbA1c reductions of 0.5–0.8% — but have a neutral effect on body weight and a very favorable safety profile. DPP-4 inhibitors are generally well tolerated and can be used across various stages of renal impairment (with appropriate dose adjustments). They carry minimal gastrointestinal side effects and do not delay gastric emptying, making them suitable for patients who cannot tolerate GLP-1 RAs.

Dual and Multi-Agonist Therapies

Recent advances include unimolecular dual agonists targeting both GLP-1 and GIP receptors (e.g., tirzepatide) or GLP-1 and glucagon receptors. Tirzepatide, a GIP/GLP-1 receptor co-agonist, has demonstrated superior glycemic control and weight loss compared to selective GLP-1 RAs in the SURPASS and SURMOUNT trials. Triple agonists (GLP-1/GIP/glucagon) are under investigation. These newer agents represent a shift toward multitarget pharmacology, aiming to harness complementary metabolic benefits.

Landmark Clinical Trials of Incretin-Based Therapies

Cardiovascular Outcomes Trials (CVOTs) for GLP-1 RAs

The FDA mandates CVOTs for new diabetes therapies to demonstrate cardiovascular safety. GLP-1 RAs have consistently shown cardiovascular benefits beyond glycemic control.

  • LEADER Trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results): Enrolled 9,340 patients with T2D and high cardiovascular risk. Liraglutide reduced the primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% (HR 0.87; 95% CI 0.78–0.97). Cardiovascular mortality was reduced by 22%. The trial established liraglutide as a first-line agent for patients with established CVD.
  • EMPA-REG OUTCOME (empagliflozin, SGLT2 inhibitor) is not incretin-based, but the precedent set by LEADER shifted focus to GLP-1 RAs.
  • REWIND Trial (Researching Cardiovascular Events with a Weekly Incretin in Diabetes): Evaluated dulaglutide in 9,901 patients with T2D and cardiovascular risk factors or established disease. Dulaglutide reduced the primary composite outcome by 12% (HR 0.88; 95% CI 0.79–0.99). Notably, benefits were observed in patients without prior CVD, supporting primary prevention.
  • SUSTAIN-6 Trial (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes): Semaglutide once weekly reduced the primary cardiovascular outcome by 26% (HR 0.74; 95% CI 0.58–0.95). Nonfatal stroke was reduced by 39%. Semaglutide also reduced albuminuria, indicating renoprotective effects.
  • PIONEER 6 Trial (Peptide Innovation for Early Diabetes Treatment): Oral semaglutide showed a non-significant trend toward cardiovascular benefit (HR 0.79; 95% CI 0.57–1.11) and confirmed safety.
  • AMPLITUDE-O Trial (Effect of Efpeglenatide on Cardiovascular Outcomes): The GLP-1 RA efpeglenatide (once weekly) reduced major adverse cardiovascular events by 27% (HR 0.73; 95% CI 0.58–0.92) in a high-risk population, further solidifying class effects.

GLP-1 RAs and Kidney Outcomes

Several CVOTs prespecified renal endpoints. LEADER showed a 22% reduction in new or worsening nephropathy. SUSTAIN-6 demonstrated a 36% reduction in worsening nephropathy. FLOW trial (semaglutide vs placebo in patients with T2D and CKD) is ongoing. A meta-analysis of GLP-1 RA CVOTs indicated a 17% reduction in the composite renal outcome (macroalbuminuria, doubling of serum creatinine, end-stage kidney disease, or renal death). These findings support the use of GLP-1 RAs for cardiorenal protection.

DPP-4 Inhibitor CVOTs

DPP-4 inhibitor trials (SAVOR-TIMI 53 for saxagliptin, EXAMINE for alogliptin, TECOS for sitagliptin, CARMELINA for linagliptin) demonstrated non-inferiority for cardiovascular safety but no superiority. Saxagliptin was associated with an increased risk of heart failure hospitalization (HR 1.27; 95% CI 1.07–1.51), leading to a boxed warning. Other DPP-4 inhibitors showed a neutral effect on heart failure. Overall, DPP-4 inhibitors are considered safe but without cardiovascular or renal benefit.

Weight Loss and Metabolic Effects

Beyond glycemic and cardiovascular benefits, GLP-1 RAs have shown substantial weight loss. Semaglutide 2.4 mg once weekly (STEP trials) achieved up to 15% weight loss in patients with obesity, leading to approval for weight management. Liraglutide 3.0 mg (SCALE trials) also induced significant weight loss. Tirzepatide in the SURMOUNT-1 trial resulted in mean weight loss of 22.5% at the highest dose. These data position incretin-based therapies as key tools in treating obesity, a major driver of T2D.

Safety, Tolerability, and Contraindications

Gastrointestinal side effects are the most common adverse events with GLP-1 RAs: nausea, vomiting, diarrhea, and constipation. They are dose-dependent and diminish over time. Gradual dose titration mitigates initial intolerance. Pancreatitis was a theoretical concern, but large trials and meta-analyses have not confirmed a causal relationship; however, labeling still advises caution in patients with a history of pancreatitis. Gallbladder-related events (cholelithiasis, cholecystitis) are increased with GLP-1 RAs, likely related to weight loss. Retinopathy complications seen in SUSTAIN-6 were attributed to rapid glucose improvement rather than direct drug effect, and subsequent trials (REWIND, LEADER) did not replicate this signal. DPP-4 inhibitors are generally well tolerated with mild infections, arthralgia, and rare hypersensitivity reactions. Acute pancreatitis has been reported rarely. Both classes carry a low risk of hypoglycemia when used as monotherapy or with metformin.

Implications for Clinical Practice and Future Directions

Current guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend GLP-1 RAs (with proven cardiovascular benefit) as preferred second-line therapy after metformin in patients with T2D and established or high risk for atherosclerotic cardiovascular disease, chronic kidney disease, or obesity. Incretin-based therapies are now integrated into a patient-centered approach emphasizing cardiorenal protection and weight loss. The emergence of oral semaglutide (first oral GLP-1 RA) improves accessibility for patients avoiding injections. Combination therapies, such as GLP-1 RA plus SGLT2 inhibitor, are being explored for additive benefits. Future research focuses on once-monthly formulations, small-molecule GLP-1 receptor agonists (non-peptide), and gut-restricted GLP-1 agonists that minimize systemic exposure. Dual and triple agonists with improved weight loss profiles (e.g., retatrutide) are in phase 3 trials. The incretin pipeline is robust, promising more potent and better-tolerated options.

Conclusion

Incretin-based therapies have evolved from experimental peptides to cornerstone treatments in diabetes and obesity management. Landmark clinical trials have confirmed their efficacy in glycemic control, weight reduction, and cardiovascular and renal protection. The differentiation between GLP-1 RAs and DPP-4 inhibitors allows clinicians to tailor therapy based on patient comorbidities and preferences. With ongoing research expanding the therapeutic horizon — from dual agonists to oral formulations — incretin-based therapies will continue to shape the future of metabolic disease management.